TScan Therapeutics Inc (TCRX)

[jondoeuk]

They plan to begin enrolling patients for screening by the middle of the year, with patient dosing expected to commence in Q3. Initial safety and biomarker data for the most advanced single-agent TCRs could be presented by the end of the year, with initial multiplex therapy data for the first combination of TCRs expected in the first half of 2024. Also, will test redosing and explore three-TCR combinations.

In addition, as the programs advance, they intend to introduce additional elements, including features designed to increase the infiltration of TCR-T cells into solid tumours, with the aim of keeping those cells active for a longer time and rendering them more impervious to different immunosuppressive tumour microenvironments.